A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression

This study is testing an experimental off-the-shelf CAR-T cell therapy that targets a protein called CD70, which is found on certain brain tumors. It is designed for people with gliomas (a type of brain cancer) that have come back or stopped responding to standard treatment. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with recurrent or refractory glioma - Your tumor has tested positive for CD70 (confirmed by tissue sample or biopsy) - Standard treatments have not worked or are no longer tolerated - You are willing to follow the study treatment and visit schedule **You may NOT be eligible if...** - Your tumor is CD70-negative on testing - You have severe organ dysfunction (heart, liver, kidney, or lung) - You have active uncontrolled infections (including HIV or hepatitis) - You are pregnant or breastfeeding - You have received CAR-T or gene therapy within a certain timeframe Talk to your doctor to see if this trial is right for you.